Semaglutide vs. Tirzepatide: Comparing the Published Efficacy Data
Trial-reported average weight-loss and blood-sugar results differ between semaglutide and tirzepatide. Here's how to read those numbers responsibly.
By the GLP Semaglutide editorial team · Last updated June 28, 2025
Published trial data has generally shown larger average weight-loss and blood-sugar reduction results for tirzepatide compared with semaglutide at their respective maximum doses, a pattern often attributed to tirzepatide's dual GIP/GLP-1 mechanism.
Averages hide individual variation
Trial averages combine a wide range of individual responses — some patients respond strongly to either drug, and some respond modestly to both. A population-level average doesn't predict any one person's result.
Cross-trial comparisons have limits
Semaglutide and tirzepatide have mostly been studied in separate trials with different populations and protocols rather than always in direct head-to-head comparisons, which is a standard caveat when comparing published results across different studies.
Primary sources